Skip to main content

Angeles Alvarez Secord

Professor of Obstetrics and Gynecology
Obstetrics and Gynecology, Gynecologic Oncology
Box 3079 Med Ctr, Durham, NC 27710
25172 Morris Bldg, Durham, NC 27710

Overview


My primary research interest has focused on on novel therapeutics, biomarkers and clinical trial development for ovarian and endometrial cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division, where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically, my focus is on biologic therapy and molecular biomarkers to direct therapy in patients with ovarian and endometrial cancers to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.

In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian and cervical cancers, as well as for benign gynecologic conditions.

Current Appointments & Affiliations


Professor of Obstetrics and Gynecology · 2013 - Present Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology
Member of the Duke Cancer Institute · 1994 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published September 18, 2024
Ovarian Cancer Therapy Trial Shows Promising Results
Published November 8, 2022
Reigniting the White House Cancer Moonshot in Gynecologic & Breast Cancers
Published January 25, 2022
On the Cover: Winter 2022 Duke Ob/Gyn Magazine

View All News

Recent Publications


Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.

Journal Article Clin Cancer Res · February 17, 2026 PURPOSE: Low-grade serous ovarian carcinoma (LGSOC) is a distinct form of ovarian cancer characterized by younger patient age and relative chemoresistance. The GOG281/LOGS trial (NCT02101788) investigated the efficacy of the MEK inhibitor trametinib compar ... Full text Link to item Cite

A phase 2 study of pembrolizumab and weekly paclitaxel for platinum-resistant epithelial ovarian cancer.

Journal Article Int J Gynecol Cancer · December 13, 2025 OBJECTIVE: Weekly dose-dense paclitaxel may have immunomodulatory effects, enhancing immune responses via cytotoxic T-cell infiltration. Therefore, we assessed the combination of weekly dose-dense paclitaxel with pembrolizumab in patients with platinum-res ... Full text Link to item Cite
View All Publications

Education


University of Washington · 1994 M.D.